Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in its own shares conducted on March 3, 2025, and filed on March 4, 2025. The filing details a share repurchase executed through Citigroup Global Markets Limited as part of an existing buyback programme under a non-discretionary agreement dated February 24, 2025.
Key Financial Metrics
The filing focuses exclusively on capital allocation activities regarding share repurchases. It does not contain revenue, profit, cash flow, margin, or debt metrics.
- Shares Purchased (March 3, 2025): 537,500 ordinary shares.
- Price Range: Lowest 1,469.00 GBp; Highest 1,495.00 GBp.
- Volume-Weighted Average Price (VWAP): 1,485.16 GBp.
- Trading Venue: London Stock Exchange (XLON).
- Cumulative Purchases (since Feb 24, 2025): 4,491,102 ordinary shares.
- Treasury Shares Held: 173,561,405 ordinary shares.
- Shares in Issue (excluding Treasury): 4,141,616,025 ordinary shares.
- Total Voting Rights: 4,141,616,025.
Material Changes
The filing reports a reduction in the number of shares in issue and an increase in treasury shares held by the company. Since the commencement of the current non-discretionary agreement on February 24, 2025, the company has repurchased over 4.4 million shares. The filing does not provide comparative financial data against prior periods as it is a transactional report rather than a financial results statement.
Guidance, Outlook, and Risks
The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties. These risks are referenced as being described in Item 3.D "Risk factors" of GSK's 2023 Annual Report on Form 20-F and its Q4 2024 Results. No specific new guidance or outlook was provided in this document.
Investor Verification Checklist
- Verify the total remaining authorization under the current buyback programme to assess future repurchase capacity.
- Confirm the impact of the increased treasury share count (173,561,405) on earnings per share (EPS) calculations.
- Review the referenced 2023 Form 20-F and Q4 2024 Results for the specific risk factors mentioned in the cautionary statement.
- Monitor subsequent filings to track the progress of the non-discretionary agreement initiated on February 24, 2025.